Innovotech Inc.
TSX VENTURE : IOT

Innovotech Inc.

June 23, 2009 06:00 ET

Innovotech Appoints New Chief Executive Officer

EDMONTON, ALBERTA--(Marketwire - June 23, 2009) - Innovotech Inc. (TSX VENTURE:IOT) ("Innovotech") has selected Mr. Ken Boutilier as its new Chief Executive Officer following the planned retirement of Dr. Wolfgang Muhs from that position. Dr. Muhs will continue in his position as Chairman of the Board of Directors of Innovotech.

"I am confident that Innovotech has the management team in place to achieve our goals and am pleased to support Ken Boutilier as we continue our commercialization efforts with our two lead products; Agress™ for the agricultural industry and bioFILM PA™ in human health. Ken Boutilier has been with Innovotech in a senior management position since the Company's inception and brings a wealth of experience to his new function" said Dr. Muhs.

In addition, Innovotech announces that the board of directors has approved a grant of stock options to Dr. Muhs to purchase 13,500 common shares pursuant to its stock option plan in acknowledgement of Dr. Muhs continued services as Chairman of the Board of Innovotech and in accordance with the 2008 compensation plan. These options have an exercise price of $0.83 per common share and expire on June 19, 2014.

About Innovotech Inc:

Innovotech is a product development company focusing on the development of solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are protected communities of microorganisms which are very common and very difficult to treat due to their inherent resistance. The company currently has two products in advanced stages of development: bioFILM PA is a diagnostic kit which assists physicians in the selection of the most effective antibiotic treatment of patients with chronic lung infections. AgressTM is a novel seed treatment product which protects seeds during the critical germination and emergence stage from bacterial and fungal infection. Both products were developed against the corresponding organisms present as biofilms as opposed to the free-floating, planktonic form.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information